224 related articles for article (PubMed ID: 35164166)
1. Investigating the Role of Obesity in Prostate Cancer and Identifying Biomarkers for Drug Discovery: Systems Biology and Deep Learning Approaches.
Yeh SJ; Chung YC; Chen BS
Molecules; 2022 Jan; 27(3):. PubMed ID: 35164166
[TBL] [Abstract][Full Text] [Related]
2. Identifying Drug Targets of Oral Squamous Cell Carcinoma through a Systems Biology Method and Genome-Wide Microarray Data for Drug Discovery by Deep Learning and Drug Design Specifications.
Lin YC; Chen BS
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142321
[TBL] [Abstract][Full Text] [Related]
3. Systems Approach to Pathogenic Mechanism of Type 2 Diabetes and Drug Discovery Design Based on Deep Learning and Drug Design Specifications.
Chang S; Chen JY; Chuang YJ; Chen BS
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33375269
[TBL] [Abstract][Full Text] [Related]
4. Systems Drug Design for Muscle Invasive Bladder Cancer and Advanced Bladder Cancer by Genome-Wide Microarray Data and Deep Learning Method with Drug Design Specifications.
Su PW; Chen BS
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430344
[TBL] [Abstract][Full Text] [Related]
5. Drug Target Identification and Drug Repurposing in Psoriasis through Systems Biology Approach, DNN-Based DTI Model and Genome-Wide Microarray Data.
Zhan YP; Chen BS
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373186
[TBL] [Abstract][Full Text] [Related]
6. Identification of prostate cancer hub genes and therapeutic agents using bioinformatics approach.
Fang E; Zhang X; Wang Q; Wang D
Cancer Biomark; 2017 Dec; 20(4):553-561. PubMed ID: 28800317
[TBL] [Abstract][Full Text] [Related]
7. Multi-target drug discovery in anti-cancer therapy: fragment-based approach toward the design of potent and versatile anti-prostate cancer agents.
Speck-Planche A; Kleandrova VV; Luan F; Cordeiro MN
Bioorg Med Chem; 2011 Nov; 19(21):6239-44. PubMed ID: 21967806
[TBL] [Abstract][Full Text] [Related]
8. General and abdominal obesity trajectories across adulthood, and risk of prostate cancer: results from the PROtEuS study, Montreal, Canada.
Vallières E; Mésidor M; Roy-Gagnon MH; Richard H; Parent MÉ
Cancer Causes Control; 2021 Jun; 32(6):653-665. PubMed ID: 33818663
[TBL] [Abstract][Full Text] [Related]
9. The role of the digital rectal examination as diagnostic test for prostate cancer detection in obese patients.
Dell'Atti L
J BUON; 2015; 20(6):1601-5. PubMed ID: 26854458
[TBL] [Abstract][Full Text] [Related]
10. CRISPR Screen Contributes to Novel Target Discovery in Prostate Cancer.
Tsujino T; Komura K; Inamoto T; Azuma H
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884583
[TBL] [Abstract][Full Text] [Related]
11. Obesity and prostate cancer: weighing the evidence.
Allott EH; Masko EM; Freedland SJ
Eur Urol; 2013 May; 63(5):800-9. PubMed ID: 23219374
[TBL] [Abstract][Full Text] [Related]
12. Obesity and prostate cancer: epidemiology and clinical implications.
Buschemeyer WC; Freedland SJ
Eur Urol; 2007 Aug; 52(2):331-43. PubMed ID: 17507151
[TBL] [Abstract][Full Text] [Related]
13. Body mass index was associated with upstaging and upgrading in patients with low-risk prostate cancer who met the inclusion criteria for active surveillance.
de Cobelli O; Terracciano D; Tagliabue E; Raimondi S; Galasso G; Cioffi A; Cordima G; Musi G; Damiano R; Cantiello F; Detti S; Victor Matei D; Bottero D; Renne G; Ferro M
Urol Oncol; 2015 May; 33(5):201.e1-8. PubMed ID: 25791753
[TBL] [Abstract][Full Text] [Related]
14. Waist circumference, waist-hip ratio, body mass index, and prostate cancer risk: results from the North-American case-control study Prostate Cancer & Environment Study.
Boehm K; Sun M; Larcher A; Blanc-Lapierre A; Schiffmann J; Graefen M; Sosa J; Saad F; Parent MÉ; Karakiewicz PI
Urol Oncol; 2015 Nov; 33(11):494.e1-7. PubMed ID: 26278366
[TBL] [Abstract][Full Text] [Related]
15. Periprostatic adipose tissue from obese prostate cancer patients promotes tumor and endothelial cell proliferation: a functional and MR imaging pilot study.
Venkatasubramanian PN; Brendler CB; Plunkett BA; Crawford SE; Fitchev PS; Morgan G; Cornwell ML; McGuire MS; Wyrwicz AM; Doll JA
Prostate; 2014 Feb; 74(3):326-35. PubMed ID: 24571013
[TBL] [Abstract][Full Text] [Related]
16. Predicting drug-target interaction network using deep learning model.
You J; McLeod RD; Hu P
Comput Biol Chem; 2019 Jun; 80():90-101. PubMed ID: 30939415
[TBL] [Abstract][Full Text] [Related]
17. Body mass index in early and middle-late adulthood and risk of localised, advanced and fatal prostate cancer: a population-based prospective study.
Discacciati A; Orsini N; Andersson SO; Andrén O; Johansson JE; Wolk A
Br J Cancer; 2011 Sep; 105(7):1061-8. PubMed ID: 21847119
[TBL] [Abstract][Full Text] [Related]
18. In1-Ghrelin Splicing Variant as a Key Element in the Pathophysiological Association Between Obesity and Prostate Cancer.
Jiménez-Vacas JM; Montero-Hidalgo AJ; Gómez-Gómez E; Fuentes-Fayos AC; Ruiz-Pino F; Guler I; Camargo A; Anglada FJ; Carrasco-Valiente J; Tena-Sempere M; Sarmento-Cabral A; Castaño JP; Gahete MD; Luque RM
J Clin Endocrinol Metab; 2021 Nov; 106(12):e4956-e4968. PubMed ID: 34255835
[TBL] [Abstract][Full Text] [Related]
19. Biomarker microRNAs for prostate cancer metastasis: screened with a network vulnerability analysis model.
Lin Y; Chen F; Shen L; Tang X; Du C; Sun Z; Ding H; Chen J; Shen B
J Transl Med; 2018 May; 16(1):134. PubMed ID: 29784056
[TBL] [Abstract][Full Text] [Related]
20. Obesity and prostate cancer detection: insights from three national surveys.
Parekh N; Lin Y; Dipaola RS; Marcella S; Lu-Yao G
Am J Med; 2010 Sep; 123(9):829-35. PubMed ID: 20800152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
